These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 8756364

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Small cell lung carcinoma exhibits greater phospholipase C-beta1 expression and edelfosine resistance compared with non-small cell lung carcinoma.
    Strassheim D, Shafer SH, Phelps SH, Williams CL.
    Cancer Res; 2000 May 15; 60(10):2730-6. PubMed ID: 10825148
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
    Jain N, Lam YM, Pym J, Campling BG.
    Cancer; 1996 May 01; 77(9):1797-808. PubMed ID: 8646677
    [Abstract] [Full Text] [Related]

  • 6. Expression of DNA topoisomerase I and DNA topoisomerase II-alpha in carcinoma of the colon.
    Staley BE, Samowitz WS, Bronstein IB, Holden JA.
    Mod Pathol; 1999 Apr 01; 12(4):356-61. PubMed ID: 10229499
    [Abstract] [Full Text] [Related]

  • 7. Expression of Y box-binding protein-1 correlates with DNA topoisomerase IIalpha and proliferating cell nuclear antigen expression in lung cancer.
    Gu C, Oyama T, Osaki T, Kohno K, Yasumoto K.
    Anticancer Res; 2001 Apr 01; 21(4A):2357-62. PubMed ID: 11724293
    [Abstract] [Full Text] [Related]

  • 8. Reduced expression of DNA topoisomerase II confers resistance to etoposide (VP-16) in small cell lung cancer cell lines established from a refractory tumor of a patient and by in vitro selection.
    Andoh T, Nishizawa M, Hida T, Ariyoshi Y, Takahashi T, Ueda R.
    Oncol Res; 1996 Apr 01; 8(6):229-38. PubMed ID: 8895198
    [Abstract] [Full Text] [Related]

  • 9. Immunohistochemical staining for DNA topoisomerase I, DNA topoisomerase II-alpha and p53 in gastric carcinomas.
    Coleman LW, Bronstein IB, Holden JA.
    Anticancer Res; 2001 Apr 01; 21(2A):1167-72. PubMed ID: 11396158
    [Abstract] [Full Text] [Related]

  • 10. Topoisomerase II alpha expression in squamous cell carcinomas of the head and neck.
    Stathopoulos GP, Kapranos N, Manolopoulos L, Papadimitriou C, Adamopoulos G.
    Anticancer Res; 2000 Apr 01; 20(1A):177-82. PubMed ID: 10769652
    [Abstract] [Full Text] [Related]

  • 11. Differential immunohistochemical staining for DNA topoisomerase II alpha and beta in human tissues and for DNA topoisomerase II beta in non-Hodgkin's lymphomas.
    Bauman ME, Holden JA, Brown KA, Harker WG, Perkins SL.
    Mod Pathol; 1997 Mar 01; 10(3):168-75. PubMed ID: 9071722
    [Abstract] [Full Text] [Related]

  • 12. Altered subcellular distribution of topoisomerase II alpha in a drug-resistant human small cell lung cancer cell line.
    Feldhoff PW, Mirski SE, Cole SP, Sullivan DM.
    Cancer Res; 1994 Feb 01; 54(3):756-62. PubMed ID: 8306338
    [Abstract] [Full Text] [Related]

  • 13. Immunohistochemical detection of DNA topoisomerase IIalpha, P-glycoprotein and multidrug resistance protein (MRP) in small-cell and non-small-cell lung cancer.
    Kreisholt J, Sorensen M, Jensen PB, Nielsen BS, Andersen CB, Sehested M.
    Br J Cancer; 1998 May 01; 77(9):1469-73. PubMed ID: 9652763
    [Abstract] [Full Text] [Related]

  • 14. Topoisomerase IIalpha gene expression is regulated by the p53 tumor suppressor gene in nonsmall cell lung carcinoma patients.
    Liu D, Huang CL, Kameyama K, Hayashi E, Yamauchi A, Sumitomo S, Yokomise H.
    Cancer; 2002 Apr 15; 94(8):2239-47. PubMed ID: 12001123
    [Abstract] [Full Text] [Related]

  • 15. Correlation between Topo II alpha expression and chemosensitivity testing for Topo II-targeting drugs in gynaecological carcinomas.
    Koshiyama M, Fujii H, Kinezaki M, Yoshida M.
    Anticancer Res; 2001 Apr 15; 21(2A):905-10. PubMed ID: 11396183
    [Abstract] [Full Text] [Related]

  • 16. Immunohistochemical expression of topoisomerase IIalpha (Topo IIalpha) and multidrug resistance-associated protein (MRP), plus chemosensitivity testing, as chemotherapeutic indices of ovarian and endometrial carcinomas.
    Koshiyama M, Fujii H, Kinezaki M, Morita Y, Nanno H, Yoshida M.
    Anticancer Res; 2001 Apr 15; 21(4B):2925-32. PubMed ID: 11712788
    [Abstract] [Full Text] [Related]

  • 17. Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression.
    Giaccone G, Gazdar AF, Beck H, Zunino F, Capranico G.
    Cancer Res; 1992 Apr 01; 52(7):1666-74. PubMed ID: 1312895
    [Abstract] [Full Text] [Related]

  • 18. Quantitation of DNA topoisomerase II alpha messenger ribonucleic acid levels in a small cell lung cancer cell line and two drug resistant sublines using a polymerase chain reaction-aided transcript titration assay.
    Withoff S, Smit EF, Meersma GJ, van den Berg A, Timmer-Bosscha H, Kok K, Postmus PE, Mulder NH, de Vries EG, Buys CH.
    Lab Invest; 1994 Jul 01; 71(1):61-6. PubMed ID: 8041119
    [Abstract] [Full Text] [Related]

  • 19. [Expression and significance of DNA topoisomerase I (topo I) in small cell lung cancer].
    Guo QS, Liu YX, Yu JM, Wang JL, Zhong WX, Liu XJ.
    Zhonghua Zhong Liu Za Zhi; 2007 Feb 01; 29(2):124-6. PubMed ID: 17645849
    [Abstract] [Full Text] [Related]

  • 20. Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide.
    Asano T, An T, Zwelling LA, Takano H, Fojo AT, Kleinerman ES.
    Oncol Res; 1996 Feb 01; 8(3):101-10. PubMed ID: 8823806
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.